- Home
- ETON vs REFI Comparison
ETON vs REFI Comparison
Compare ETON & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- REFI
- Stock Information
- Founded
- ETON 2017
- REFI 2021
- Country
- ETON United States
- REFI United States
- Employees
- ETON N/A
- REFI N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- REFI Real Estate Investment Trusts
- Sector
- ETON Health Care
- REFI Real Estate
- Exchange
- ETON Nasdaq
- REFI Nasdaq
- Market Cap
- ETON 428.5M
- REFI 291.9M
- IPO Year
- ETON 2018
- REFI 2021
- Fundamental
- Price
- ETON $17.33
- REFI $14.85
- Analyst Decision
- ETON Strong Buy
- REFI Strong Buy
- Analyst Count
- ETON 3
- REFI 3
- Target Price
- ETON $27.67
- REFI $20.00
- AVG Volume (30 Days)
- ETON 221.4K
- REFI 112.2K
- Earning Date
- ETON 05-13-2025
- REFI 05-07-2025
- Dividend Yield
- ETON N/A
- REFI 13.87%
- EPS Growth
- ETON N/A
- REFI N/A
- EPS
- ETON N/A
- REFI 1.88
- Revenue
- ETON $39,011,000.00
- REFI $56,790,054.00
- Revenue This Year
- ETON $92.33
- REFI $17.87
- Revenue Next Year
- ETON $52.62
- REFI N/A
- P/E Ratio
- ETON N/A
- REFI $7.90
- Revenue Growth
- ETON 23.29
- REFI 4.68
- 52 Week Low
- ETON $3.18
- REFI $12.76
- 52 Week High
- ETON $18.41
- REFI $16.47
- Technical
- Relative Strength Index (RSI)
- ETON 68.29
- REFI 59.49
- Support Level
- ETON $16.43
- REFI $14.50
- Resistance Level
- ETON $17.49
- REFI $14.81
- Average True Range (ATR)
- ETON 0.88
- REFI 0.27
- MACD
- ETON 0.19
- REFI 0.12
- Stochastic Oscillator
- ETON 92.78
- REFI 93.44
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.